方法：收集我院2015-01/11确诊为新生血管性青光眼患者14例14眼，依次行玻璃体腔雷珠单抗注射、PPR及复合小梁切除术治疗。观察术后眼压、视力、虹膜新生血管及术中术后并发症的情况。

结果：经3～6mo观察及随访，末次随访平均眼压为18.00±6.70mmHg，较术前平均眼压(41.65±4.07mmHg)有显著降低(t=11.288，P<0.05)。手术成功定义为未辅助用降眼压药物，眼压<21mmHg； 有效定义为辅助用降眼压药物，眼压<21mmHg。末次随访11眼眼压<21mmHg，成功率为79%； 2眼有效(14%)； 1眼失败，眼压失控后行睫状体冷冻治疗。视力检查结果显示6眼稍有提高，7眼不变，1眼减退； 13眼虹膜新生血管消失，1眼在随访的第3mo消失的虹膜新生血管又复现，给予再次玻璃体腔雷珠单抗注射并补充眼底视网膜激光治疗后消失； 术后前房积血1眼，1wk后吸收，未出现术后浅前房及眼球萎缩患者。

结论：玻璃体腔雷珠单抗注射及复合小梁切除术联合PPR治疗新生血管性青光眼安全、可靠，疗效确定。

METHODS:A total of 14 cases(14 eyes)with NVG were collected from January to November 2015. All cases were treated with intravitreal lucentis injection, PPR and compound trabeculectomy by turns. Intraocular pressure(IOP), visual acuity and the complications at pre-or post-surgery were recorded, respectively.

RESULTS: Followed up for 3-6mo, the average IOP preoperatively was significantly decreased than that detected at post-operation(18.00±6.70 vs 41.65±4.07mmHg, t=11.288, P<0.05). IOP less than 21mmHg with or without the usage of anti-intraocular pressure drugs was defined as the sign of successful or effective surgery, respectively. At the ultimate follow-up, 11 cases were successful, 2 cases were effective, and the success rate was 79%, effective rate was 14%. Only 1 case was applied cyclocryotherapy due to the uncontrolled IOP. Moreover, the results of visual acuity detection demonstrated that 6 eyes got a better visual acuity, 7 eyes remained the same condition and 1 case got no light perception. Meanwhile, 13 cases showed none iris neovascularization during the follow-up; 1 case got a reappearance of iris neovascularization on the third month, which was then dissolved subjected to the intravitreal lucentis injection in combination with PPR. One case developed post-operative hyphema and absorbed after 1wk. No shallow anterior chamber and eyeball atrophy happened.

CONCLUSION:Intravitreal lucentis injection combined with PPR and compound trabeculectomy is an effective and safe therapeutic strategy for the treatment of NVG.